Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Published in: The Annals of pharmacotherapy (2021)

The FDA approval of melflufen in combination with dexamethasone provides an additional therapy option for patients with heavily pretreated relapsed and refractory multiple myeloma.

Keyphrases

multiple myeloma
low dose
high dose
acute lymphoblastic leukemia
cancer therapy
emergency department
adverse drug
bone marrow
electronic health record